TY - JOUR
T1 - Meeting the challenges of an emerging pathogen
T2 - The Henry Schueler 41&9 foundation international forum on mucormycosis
AU - Walsh, Thomas J.
AU - Bloom, Bruce E.
AU - Kontoyiannis, Dimitrios P.
N1 - Funding Information:
Potential conflicts of interest. T. J. W. has received grant support from Novartis and Astellas and has served as a consultant for Trius, iCo, Sigma Tau, Draius, and Novartis. D. K. has served on the board and received consultancy support from Schering-Plough and Merck. B. B. reports no potential conflicts of interest.
PY - 2012/2/1
Y1 - 2012/2/1
N2 - Invasive mucormycosis comprises a group of uncommon but emerging life-threatening pulmonary, sinal, rhinocerebral, and disseminated infections, which cause debilitating morbidity and severe mortality in our most vulnerable pediatric and adult immunocompromised patients. While important advances are being achieved in understanding the epidemiology, molecular taxonomy, pathogenesis, pharmacology, host defenses, and microbiology of these infections, there are critical needs for improving these approaches for diagnosis, treatment, and prevention. This supplement is dedicated to the memory and courage of Hank Schueler, who fought valiantly against this infection. It provides a comprehensive resource for current approaches to management of this infection and also reviews the key advances against invasive mucormycosis.
AB - Invasive mucormycosis comprises a group of uncommon but emerging life-threatening pulmonary, sinal, rhinocerebral, and disseminated infections, which cause debilitating morbidity and severe mortality in our most vulnerable pediatric and adult immunocompromised patients. While important advances are being achieved in understanding the epidemiology, molecular taxonomy, pathogenesis, pharmacology, host defenses, and microbiology of these infections, there are critical needs for improving these approaches for diagnosis, treatment, and prevention. This supplement is dedicated to the memory and courage of Hank Schueler, who fought valiantly against this infection. It provides a comprehensive resource for current approaches to management of this infection and also reviews the key advances against invasive mucormycosis.
UR - http://www.scopus.com/inward/record.url?scp=84855897249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855897249&partnerID=8YFLogxK
U2 - 10.1093/cid/cir862
DO - 10.1093/cid/cir862
M3 - Article
C2 - 22247440
AN - SCOPUS:84855897249
SN - 1058-4838
VL - 54
SP - S1-S4
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 1
ER -